Iyengar Yoga for Young People With Rheumatoid Arthritis
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Rheumatoid Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 16 - 35 |
| Updated: | 4/2/2016 |
| Start Date: | June 2009 |
| End Date: | May 2011 |
| Contact: | Laura A Cousins, B.A. |
| Email: | lcousins@mednet.ucla.edu |
| Phone: | 310 500 8681 |
The purpose of this study is to compare a standardized 6 week Iyengar Yoga program (IYP) for
adolescents and young adults with rheumatoid arthritis to a standard care wait-list
condition. In addition to effects on function and pain, this study will explore intervention
effects on disease activity, immune response, HRQOL, functionality, and mood. Results will
shed light on the feasibility and potential efficacy of a novel intervention (Iyengar yoga)
for rheumatoid arthritis symptoms.
The hypotheses are:
1. The IYP will be safe, acceptable and feasible: at least 80% of subjects will complete
the IYP.
2. Following the IYP, participants will show significantly improved disease status,
general functioning, arthritis-functioning and HRQOL relative to controls. The benefits
will be apparent post-treatment and at two-month follow-up.
3. Following the IYP, participants will report significantly improved pain, immune
response and mood compared to controls. These improvements will be evident at both
post-treatment and at two-month follow-up.
adolescents and young adults with rheumatoid arthritis to a standard care wait-list
condition. In addition to effects on function and pain, this study will explore intervention
effects on disease activity, immune response, HRQOL, functionality, and mood. Results will
shed light on the feasibility and potential efficacy of a novel intervention (Iyengar yoga)
for rheumatoid arthritis symptoms.
The hypotheses are:
1. The IYP will be safe, acceptable and feasible: at least 80% of subjects will complete
the IYP.
2. Following the IYP, participants will show significantly improved disease status,
general functioning, arthritis-functioning and HRQOL relative to controls. The benefits
will be apparent post-treatment and at two-month follow-up.
3. Following the IYP, participants will report significantly improved pain, immune
response and mood compared to controls. These improvements will be evident at both
post-treatment and at two-month follow-up.
Inclusion Criteria:
- People with rheumatoid arthritis between the ages of 16-35
- Diagnosis of RA, according to the revised 1987 ACR criteria, or juvenile idiopathic
arthritis (JIA) for at least 6 months
- Concomitant use of disease modifying antirheumatic medications (hydroxychloroquine,
sulfasalazine, methotrexate, leflunomide, etc) biologic agents (infliximab,
etanercept, adalimumab, abatacept, rituximab, anakinra) is permitted provided that
the dose(s) have been stable for 4 weeks prior to screening, and may reasonably be
expected to remain on stable doses throughout the duration of the trial
- Concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) and low dose
corticosteroids (e.g prednisone at doses of 10 /day prednisone or equivalent is
permitted provided that the dose(s) have been stable for 4 weeks prior to screening,
and may reasonably be expected to remain on stable doses throughout the duration of
the trial
- Disease activity, as defined using a 28 joint count by > 5 tender joints, > 5 swollen
joints, and one of the following: ESR > 28 mm/hour, CRP > 1.5 mg/dL, duration of a.m.
stiffness > 45 minutes
- Ability to provide written informed consent
- Ability to speak and understand English
Exclusion Criteria:
- Intra-articular steroid injections within 4 weeks of screening
- Treatment with any investigational agent within 8 weeks of screening or 5 half-lives
of the investigational drug (whichever is longer)
- History of drug, alcohol, or chemical abuse within 6 months prior to screening
- Any other disease, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion that might affect the interpretation
of the results or render the patient at high risk from treatment complications
- Inability to comply with study and follow-up procedures
- Currently pregnant
- Inability to speak or understand English
- Any recent injury.
We found this trial at
1
site
Click here to add this to my saved trials
